For founders and investors deep in the cardiac AI world, the liquidity question is always there. An IPO is the shiny object everyone talks about, but a strategic sale to a big healthcare player is a proven, and often just as profitable, way out. You can’t treat these as Plan A and Plan B. You have to think of them as two parallel capital plans from the start, because what you need to prove for an IPO is different from what you need for a sale. Getting this right is how you maximize returns and make sure your tech actually has an impact.
The Public Offering: HeartFlow’s Listing
The IPO route is best seen through HeartFlow’s listing in August 2025. After years of private funding, with major backing from Bain Capital, HeartFlow pulled in $364 million, a huge signal of market confidence in its CT-FFR technology. It showed that public markets are ready to buy into cardiac AI, but only if it’s clinically validated, has regulatory clearance, and can show a real path to better patient care and lower costs. HeartFlow’s common stock began trading on the Nasdaq Global Select Market on August 8, 2025, under the ticker symbol “HTFL”. The total gross proceeds, after the underwriters exercised their option to buy more shares, came out to about $364.2 million. If you’re going to try and go public, you’re signing up for a long, hard slog of building a real commercial machine, a patent portfolio thick enough to stop any challenger, and a perfect regulatory history. HeartFlow spent years on clinical validation, getting its 510(k) clearances, and proving its SaMD was useful before it could even think about its public debut. When you go this route, investors will pick apart your tech, sure, but they’re also asking if you can scale, how you’ll manage algorithmic drift, and whether you have a clue how to get paid in the mess that is reimbursement. The street wants to see a real data moat and a competitive advantage you can sustain, which usually means tons of real-world evidence and a rock-solid GMLP framework.
The Strategic Sale: A Recorded Alternative for Cardiac AI Assets
While HeartFlow was going public, plenty of other cardiac AI companies were getting acquired by bigger healthcare players. This is a common story. This path is attractive if you want to plug into a major company’s existing sales channels, payer contracts, and regulatory teams instead of building your own from scratch. The acquirer usually sees it as a “bolt-on” deal, they’re buying your AI to stick it into their product line and give them an edge or a more complete offering for their hospital customers. A strategic sale isn’t a fire sale. Like an IPO, it’s the result of years of careful work. If you’re aiming for this, your focus changes. You’re not building a standalone company. You’re building a perfect “wedge product” that fits neatly into a bigger company’s platform, demonstrating how your tech is compatible and what value it adds. How mature is your QMS and ISO 13485 certification? How clean is your IP? Does your tech solve a problem the acquirer is desperate to fix? That’s what matters. The due diligence for a sale is intense, and they’ll have auditors crawling all over your HIPAA compliance, HITRUST certification, and SOC 2 reports to make sure your data security is up to their enterprise standards.
Evidence and Clearance: Keeping Both Routes Open
It doesn’t matter which exit you want. You can’t get there without a mountain of clinical evidence and proper regulatory clearance. It’s non-negotiable. Look at Cleerly, grinding it out to build clinical proof for its plaque quantification program, or Eko Health, which owns a cleared position in cardiac screening. They show how critical this work is. Cleerly’s long-term investment in validating its plaque program is exactly the kind of long game you have to play in cardiac AI. You need strong trials and real-world evidence to show your AI tool is effective and safe. That evidence is what you take to the FDA to get your 510(k) or a De Novo classification for something totally new. AMA CPT code application process More importantly, all that clinical data is the foundation for getting paid, it’s how you argue for CPT codes (Category I or III) and maybe even an NTAP designation. A solid body of evidence makes both public investors and private acquirers feel safe, showing them you have a clear shot at commercial success and getting payers on board. Eko Health’s cleared screening position shows just how big a deal regulatory wins are. But getting a 510(k) clearance is a huge achievement that’s often just the start. You need a clear regulatory strategy that includes a plan for things like predetermined change control plans (PCCPs), which is how you’ll manage your AI models as they learn and adapt. Both investors and acquirers want to back companies that get the regulatory game, know the ins and outs of things like CE Mark / EU MDR for selling in Europe, and can explain their plan for the next version of the product. The line between being a clinical decision support tool and a full-on diagnostic AI is also critical, as it determines your entire regulatory burden and how you can position yourself in the market.
Exit Strategy as a Capital-Planning Question
When you look at the paths of HeartFlow, Cleerly, and Eko Health together, you see the real story: your exit strategy is a capital-planning question you have to answer on day one. That choice of exit dictates what kind of evidence you gather, how much money you pour into payer strategy, and how you structure the company. If you’re aiming for an IPO, you have to build a complete, standalone business that can survive public scrutiny. That means spending huge amounts on sales, marketing, and corporate governance on top of your product work. The goal is to show a massive total addressable market (TAM), a business model that scales, and a believable story about future profitability. SEC guidance on IPO requirements On the other hand, a company building for a strategic sale might focus on deep technical integration capabilities and developing a very specialized product that fills a hole in a big company’s portfolio. You might even think about cultural fit with potential buyers. Clinical validation and regulatory clearance are still table stakes, but your commercial plan might be less about hiring a 100-person sales team and more about proving your product works perfectly inside someone else’s system. This could mean finding a niche or a “wedge product” that an acquirer can easily adopt and scale for you. The most successful cardiac AI founders are the ones who get that the liquidity event isn’t some far-off dream. It’s the organizing principle for the entire company. It drives every decision you make, from early product development to late-stage commercialization, making sure you’re building the right assets and evidence to get to your financial and clinical goals. The market has no patience for zombie companies drifting without a plan. A clear, well-executed exit strategy, whether an IPO or a strategic sale, is what separates a science project from a truly investable cardiac AI company.
Frequently Asked Questions
What are the primary liquidity routes for cardiac AI companies?
The primary liquidity routes are an Initial Public Offering (IPO) and a strategic sale to an established healthcare entity. Both are considered parallel capital plans, each with distinct demands on evidence and payer strategy.
What are the key requirements for a successful IPO in cardiac AI?
A successful IPO demands a long-term commitment to building a robust commercial infrastructure, a deep patent thicket, and an impeccable regulatory track record. Companies must demonstrate clinical validation, regulatory clearances, scalability, and a clear data moat with sustainable competitive advantage.
What makes a strategic sale an attractive option for cardiac AI companies?
A strategic sale allows companies to leverage an incumbent’s established distribution channels, payer relationships, and regulatory expertise. It often involves developing a wedge product that integrates seamlessly into a larger platform, demonstrating clear value and technological compatibility.
What foundational elements are critical for both IPOs and strategic sales?
Regardless of the chosen exit path, robust clinical evidence and regulatory clearance are non-negotiable. This includes strong clinical trials, real-world evidence, securing regulatory approvals like 510(k) clearances, and a clear regulatory strategy for future product iterations.